TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29319386

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) and shoulder/neck exercises
Number of subjects: 43

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 43
Study: 25750519

Group type: EXPERIMENTAL
Intervention: Test drug (tramadol formulation)
Number of subjects: 0
Study: 24211751

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 21675059

Group type: EXPERIMENTAL
Intervention: Daily sedation interruption
Number of subjects: 699

Group type: COMPARATOR
Intervention: No sedation interruption
Number of subjects: 699
Study: 19319008

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Base-in prism reading glasses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based therapy (pencil push-ups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 0
Study: 18001519

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (4.6 mg/24 hour, 5 cm²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 hour, 10 cm²)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine capsules (3 mg BID, 6 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivastigmine capsules (6 mg BID, 12 mg/day)
Number of subjects: 0
Study: 14734002

Group type: EXPERIMENTAL
Intervention: 15 micrograms of D17DT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 micrograms of D17DT
Number of subjects: 12
Study: 11137809

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with posterior chordal preservation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mitral valve replacement with chordal transection
Number of subjects: 56
Study: 8419555

Group type: EXPERIMENTAL
Intervention: Bromocriptine, 1.25 mg, three times per day for two weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3532784

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Flexibility exercises (Control)
Number of subjects: 34
Study: 27974550

Group type: EXPERIMENTAL
Intervention: HM‐JACKarc
Number of subjects: 48888

Group type: COMPARATOR
Intervention: OC‐Sensor
Number of subjects: 48888
Study: 25193822

Group type: EXPERIMENTAL
Intervention: Mechanochemical ablation (ClariVein®)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Radiofrequency ablation (Covidien® Venefit™)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study: 25020155

Group type: EXPERIMENTAL
Intervention: Intervention (2-session intervention aimed at increasing adherence)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (similar levels of non-medication-related contact)
Number of subjects: 62
Study: 23635728

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500 mg, three times daily)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg, three times daily)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 21068481

Group type: EXPERIMENTAL
Intervention: Epoetin beta 10,000 IU thrice weekly (TW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 IU once weekly (OW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epoetin beta therapy (both schedules)
Number of subjects: 100
Study: 18191071

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (demographics, medical history, anthropometry)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Demographics and medical history
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 5145
Study: 17190179

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 31
Study: 14987200

Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 56

Group type: COMPARATOR
Intervention: BMT
Number of subjects: 56
Study: 10933122

Group type: EXPERIMENTAL
Intervention: Childhood Uniform Assessment Package (CUAP)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine assessment and treatment as usual (ATU)
Number of subjects: 250
Study: 8959163

Group type: EXPERIMENTAL
Intervention: 2 sutures
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2 staples
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 staples
Number of subjects: 10
Study: 1573032

Group type: EXPERIMENTAL
Intervention: Tranylcypromine (TCP) 30 mg (target dose), actual mean dose 18.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 150 mg (target dose), actual mean dose 114.3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of TCP and AMI (target doses: TCP 30 mg, AMI 150 mg; actual mean doses: TCP 19.7 mg, AMI 108.7 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3523369

Group type: EXPERIMENTAL
Intervention: Topically administered alpha‐adrenoceptor agonist (phenylpropanolamine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30143396

Group type: EXPERIMENTAL
Intervention: Computer-controlled delivery system
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 76
Study: 27439227

Group type: EXPERIMENTAL
Intervention: Counseling sessions with a therapist utilizing motivational interviewing techniques
Number of subjects: 204

Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 204
Study: 23523540

Group type: EXPERIMENTAL
Intervention: High-frequency vibration training (32 Hz, 1mm, 4 g)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-frequency vibration training (18 Hz, 3 mm, 4 g)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 50
Study: 22774940

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Assessment Program (CHAP)
Number of subjects: 46
Study: 21977860

Group type: EXPERIMENTAL
Intervention: Zishengukang Pill with Western medicine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 64
Study: 19111362

Group type: EXPERIMENTAL
Intervention: PTV(4D)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PTV(3CT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PTV(conv)
Number of subjects: 10
Study: 16927568

Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate (OROS-MPH, Concerta)
Number of subjects: 213

Group type: COMPARATOR
Intervention: IR-Methylphenidate (IR-MPH)
Number of subjects: 213
Study: 15314810

Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic function (restrictive filling pattern)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Left ventricular systolic function
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, wall motion score index (WMSi), history of previous MI, diabetes mellitus
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, congestive heart failure
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: History of systemic hypertension, wall motion score index, diabetes mellitus
Number of subjects: 520
Study: 11738228

Group type: EXPERIMENTAL
Intervention: WARIS‐II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ESCAMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAFAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RITZ‐I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIME
Number of subjects: 0
Study: 9310720

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone acetate 0.5% (Cortaid Cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% (Eumovate Cream)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% (Clobesol Cream)
Number of subjects: 0
Study: 7870986

Group type: EXPERIMENTAL
Intervention: Nicotine gum for 1 month
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nicotine gum for 3 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 128
Study: 2430606

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vecuronium 0.12 mg kg‐1
Number of subjects: 20
Study: 30071333

Group type: EXPERIMENTAL
Intervention: C1‐C2 fusion
Number of subjects: 165

Group type: COMPARATOR
Intervention: Occipito-Cervical (O-C) fusion
Number of subjects: 165

Group type: COMPARATOR
Intervention: O-C fusion
Number of subjects: 165
Study: 27020669

Group type: EXPERIMENTAL
Intervention: High-salt diet plus potassium supplement for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: High-salt diet
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Jurkat cells treated with 40 mM NaCl
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Jurkat cells treated with additional 2 mM KCl
Number of subjects: 49
Study: 24998242

Group type: EXPERIMENTAL
Intervention: Cognitive working memory training (computer-based program, 25 daily sessions over 5 to 6 weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 115
Study: 21835953

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (ASA) 100 mg/d (n = 176)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg/d (n = 166)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Both ASA and LMWH
Number of subjects: 342
Study: 19832854

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) - human recombinant PTH 1-34, 20 microg daily injections for 18 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (16 age- and gender-matched)
Number of subjects: 31
Study: 18698292

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Number of subjects: 693

Group type: COMPARATOR
Intervention: Focal/grid photocoagulation
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 693
Study: 15952104

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 1.5 microg/kg/wk
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 3.0 microg/kg/wk
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alfa 2b 1.5 or 3.0 microg/kg/wk (split-dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: IFN‐alfa 2b 3 mIU 3 times weekly
Number of subjects: 61
Study: 12072849

Group type: EXPERIMENTAL
Intervention: EMG signal of the paraspinal musculature at L3 during quiet stance using different normalization techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral asymmetry of paraspinal musculature in segments exhibiting pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dynamic asymmetry of paraspinal musculature during forward bending
Number of subjects: 0
Study: 10332129

Group type: EXPERIMENTAL
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3 percent mepivacaine
Number of subjects: 42
Study: 8739019

Group type: EXPERIMENTAL
Intervention: S-1452 (10 mg, 25 mg, 50 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1763923

Group type: EXPERIMENTAL
Intervention: Nicardipine LA 50 mg administered twice daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6980756

Group type: EXPERIMENTAL
Intervention: Allogeneic tumor vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not receiving tumor vaccine)
Number of subjects: 40
Study: 30334124

Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation therapy (lPBMt) with an exercise program for 8 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (UST) with an exercise program for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with only the exercise program for 8 weeks
Number of subjects: 45
Study: 28129246

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 25956261

Group type: EXPERIMENTAL
Intervention: 37 °C group
Number of subjects: 1338

Group type: COMPARATOR
Intervention: RT group
Number of subjects: 1338
Study: 24360649

Group type: EXPERIMENTAL
Intervention: Smokers (both depressed and non-depressed)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Depressed non-smokers
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-smokers who are not depressed
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Depressed non-smokers and both groups of smokers
Number of subjects: 80
Study: 22646848

Group type: EXPERIMENTAL
Intervention: mHealth cardiac rehabilitation exercise intervention
Number of subjects: 20
Study: 19491386

Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid, 500 mg every day)
Number of subjects: 8171

Group type: EXPERIMENTAL
Intervention: Vitamin E (RRR‐alpha‐tocopherol acetate, 600 IU every other day)
Number of subjects: 8171

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg every other day)
Number of subjects: 8171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8171
Study: 16937979

Group type: EXPERIMENTAL
Intervention: 40 g.d(‐1) of whey protein + 8 g.d(‐1) of casein (WC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 40 g.d(‐1) of whey protein + 3 g.d(‐1) branched-chain amino acids + 5 g.d(‐1) L-glutamine (WBG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 48 g per day (g.d(‐1)) carbohydrate placebo (P)
Number of subjects: 36
Study: 14962152

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg and rifampin 300 mg daily for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 11738746

Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine (PSV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (conjugate Haemophilus influenzae type b (HbOC) vaccine)
Number of subjects: 60
Study: 9158644

Group type: EXPERIMENTAL
Intervention: Indobufen (100 or 200 mg BID)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Warfarin (to obtain an international normalized ratio of 2.0 to 3.5)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Warfarin (control group)
Number of subjects: 916
Study: 7714411

Group type: EXPERIMENTAL
Intervention: Diclofenac Na
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Flurbiprofen Na
Number of subjects: 165
Study: 3067479

Group type: EXPERIMENTAL
Intervention: Pentoxifyllin 1200 mg daily for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (39 infertile men)
Number of subjects: 90
Study: 30186817

Group type: EXPERIMENTAL
Intervention: Anti-T-lymphocyte globulin (ATG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basiliximab (BAS)
Number of subjects: 40
Study: 28954926

Group type: EXPERIMENTAL
Intervention: ARC-520 (RNA interference-based therapeutic targeting HBV transcripts)
Number of subjects: 0
Study: 26154657

Group type: EXPERIMENTAL
Intervention: Native banana starch (NBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digestible corn starch (DCS)
Number of subjects: 0
Study: 23763082

Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1% for 2 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Vehicle for 2 weeks
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1% for 4 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Vehicle for 4 weeks
Number of subjects: 147
Study: 21398574

Group type: EXPERIMENTAL
Intervention: ProDisc-L total disc replacement
Number of subjects: 237

Group type: COMPARATOR
Intervention: Circumferential arthrodesis
Number of subjects: 237
Study: 18297353

Group type: EXPERIMENTAL
Intervention: Standard colonoscope with transparent hood
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard colonoscope without transparent hood
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Small-caliber colonoscope with transparent hood
Number of subjects: 372

Group type: COMPARATOR
Intervention: Small-caliber colonoscope without transparent hood
Number of subjects: 372
Study: 16091238

Group type: EXPERIMENTAL
Intervention: STI interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective treatment of curable STIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical services related to STI interventions
Number of subjects: 0
Study: 11601117

Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg, once daily)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 9606227

Group type: EXPERIMENTAL
Intervention: Immediate bolus strategy (3 mL intratracheal bolus of calf lung surfactant extract - Infasurf administered before positive pressure ventilation)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Postventilatory aliquot strategy (3 mL of surfactant administered in 4 divided aliquots of 0.75 mL each at 10 minutes after birth)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Immediate bolus strategy
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Postventilatory aliquot strategy
Number of subjects: 651
Study: 7740450

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 150 U/kg s.c.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low dose LMWH 35 U/kg s.c.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose LMWH 75 U/kg s.c.
Number of subjects: 18

Group type: COMPARATOR
Intervention: UFH and LMWH
Number of subjects: 18
Study: 2557322

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g NaHCO3/kg body wt)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.12 g NaHCO3/kg body wt initially, with 0.18 g/kg body wt distributed in equal doses before each 5‐min exercise bout)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Calcium carbonate (placebo control)
Number of subjects: 6
Study: 1222886

Group type: EXPERIMENTAL
Intervention: C-3 (2 g statim plus 6 g by continuous drip infusion over 24 hrs for 5 days)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-3
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-3 (for more than 24 hours)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-3 (for more than 12 hours, male patients)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-3 (for patients less than 60 years old)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-3 (for patients less than 60 years old, for more than 12 hours)
Number of subjects: 391
Study: 30389750

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 28485320

Group type: EXPERIMENTAL
Intervention: Aerosolized Amikacin (400 mg, q8h) for 7 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline, 4 ml, q8h) for 7 days
Number of subjects: 52
Study: 25659550

Group type: EXPERIMENTAL
Intervention: Conventional herniotomy (Group A)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Mini-invasive herniotomy (Group B)
Number of subjects: 784
Study: 23714133

Group type: EXPERIMENTAL
Intervention: Symptomatic femoroacetabular impingement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy, pain-free control group
Number of subjects: 30
Study: 22118109

Group type: EXPERIMENTAL
Intervention: Ceftiofur hydrochloride intramammary infusion at 24-hour intervals for 5 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ceftiofur hydrochloride intramammary infusion
Number of subjects: 104
Study: 19201570

Group type: EXPERIMENTAL
Intervention: Stress echocardiography with low ejection fraction
Number of subjects: 3259

Group type: EXPERIMENTAL
Intervention: Stress echocardiography with extent of ischemia
Number of subjects: 3259

Group type: EXPERIMENTAL
Intervention: Ejection fractions < 30%
Number of subjects: 3259
Study: 17110799

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 or 50 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15222407

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Simvastatin (40 mg)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 325

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 325
Study: 11250189

Group type: EXPERIMENTAL
Intervention: Washed postoperative drainage fluid (Group A)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Blood processed from the cardiopulmonary bypass (CPB) circuit (Group B)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 166
Study: 9218208

Group type: EXPERIMENTAL
Intervention: Trandolapril and verapamil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Trandolapril alone
Number of subjects: 100
Study: 8317790

Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 0.6 mg twice daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 2.5 mg twice daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aerosolized recombinant human deoxyribonuclease (rhDNase) 10.0 mg twice daily
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 2952213

Group type: EXPERIMENTAL
Intervention: D‐Trp‐6‐LHRH
Number of subjects: 104

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 104
Study: 29608427

Group type: EXPERIMENTAL
Intervention: 6 second interval
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12 second interval
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 second interval
Number of subjects: 40
Study: 26253453

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 23897769

Group type: EXPERIMENTAL
Intervention: golimumab+MTX
Number of subjects: 461
Study: 22739373

Group type: EXPERIMENTAL
Intervention: Salmon consumption (2 portions of farmed salmon per week providing 3.45 g long‐chain (LC) (n‐3) PUFA/wk)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Salmon consumption
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123